MedPath

Metabolomics of the Dietary Approaches to Stop Hypertension (DASH) Dietary Pattern

Completed
Conditions
Blood Pressure
Dietary Modification
Registration Number
NCT03403166
Lead Sponsor
Johns Hopkins Bloomberg School of Public Health
Brief Summary

The present record represents a secondary data analysis of the Dietary Approaches to Stop Hypertension (DASH) trial. Study data and specimens were accessed through the National Heart, Lung, and Blood Institute (NHLBI) Biologic Specimen and Data Repository Coordinating Center (BioLINCC). A global, untargeted, metabolomic profile was used to investigate biomarkers of the DASH dietary pattern as well as blood pressure change.

Detailed Description

The present study was conducted in order to: 1) quantify the metabolomic expression of the DASH dietary pattern; and 2) examine the relationship between metabolites that reflect the DASH dietary pattern and blood pressure change. This secondary data analysis leverages the completed DASH trial, a randomized feeding trial (N=459).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
459
Inclusion Criteria
  • Men and women with systolic blood pressure <160 mmHg and diastolic blood pressure 80-95 mmHg
Exclusion Criteria
  • Taking anti-hypertensive medication
  • Poorly controlled diabetes mellitus
  • Hyperlipidemia
  • Cardiovascular event within the past 6 months
  • Chronic disease that may interfere with participation
  • Pregnancy or lactation
  • Body mass index > 35 kg/m2
  • Unwilling to stop taking vitamin or mineral supplements or antacids
  • Kidney disease
  • Consumption of >14 alcoholic beverages per week
  • Did not consent to the use of biological specimens
  • Did not attend the 8 week follow-up visit
  • No serum specimen or insufficient volume of serum specimens in repository

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum metabolites8 week follow-up visit

Metabolites were measured using a global, untargeted, metabolomic platform in serum specimens collected at the end of the 8 week diet intervention in the DASH trial. Reverse phase, untargeted ultrahigh-performance liquid chromatography tandem mass spectrometry quantification was used to measure metabolites. Peaks were quantified by calculating the area under the curve. Data were normalized to account for day-to-day instrumental variation. Compounds were identified by comparison to a library of purified standards or recurrent unknown entities and matches were determined based on retention time, mass-to-charge ratio, and chromatographic data. A relative measure of each metabolite (not absolute) is determined. The Metabolon (Durham, NC) platform quantifies over 1,000 compounds representing a broad range of metabolic compounds, including amino acids, carbohydrates, cofactors and vitamins, energy, lipids, nucleotides, peptides, and xenobiotics (chemicals, drugs, and food components).

Secondary Outcome Measures
NameTimeMethod
Blood pressure8 week follow-up visit

The change in blood pressure was defined as the blood pressure level at the end of the 8 week diet intervention minus the blood pressure level at baseline.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.